Elevated interleukin (IL)-17 levels are increasingly ... The investigators suggest that IL-6 might be the culprit and could, therefore, be a candidate for future studies of myositis therapy.

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...